摘要: Currently, the backbone of therapy for metastatic disease is cytotoxic chemotherapy, along with recent addition targeted based on molecular markers KRAS testing. Despite improvement in survival colon cancer, newer agents are still needed. The clinical activity TroVax cancer has been studied a small number trials. There evidence that supports vaccine's ability to induce humoral and cellular responses, as demonstrated by positive 5T4 MVA-specific antibody titers proliferation assays. Future strategies should focus investigating immunomodulatory effects chemotherapy conjunction TroVax, understanding optimal dosing schedule combination, examining potential predictive biomarkers determine which patients may benefit from immunotherapy those who do not.
sci-hub.se 参考文章(31)
Rodryg Ramlau, Elisabeth Quoix, Janusz Rolski, Miklos Pless, Herve Lena, Eric Lévy, Maciej Krzakowski, Dagmar Hess, Eric Tartour, Marie-Pierre Chenard, Jean-Marc Limacher, Nadine Bizouarne, Bruce Acres, Céline Halluard, Thierry Velu, A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 3, pp. 735- 744 ,(2008) , 10.1097/JTO.0B013E31817C6B4F
R. Dreicer, W. M. Stadler, F. R. Ahmann, T. Whiteside, N. Bizouarne, B. Acres, J.-M. Limacher, P. Squiban, A. Pantuck, MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Investigational New Drugs. ,vol. 27, pp. 379- 386 ,(2009) , 10.1007/S10637-008-9187-3
Don G. Morris, Xiaolan Feng, Lisa M. DiFrancesco, Kevin Fonseca, Peter A Forsyth, Alexander H. Paterson, Matt C. Coffey, Brad Thompson, REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors Investigational New Drugs. ,vol. 31, pp. 696- 706 ,(2013) , 10.1007/S10637-012-9865-Z
Richard Harrop, Noel Drury, William Shingler, Priscilla Chikoti, Irina Redchenko, Miles W. Carroll, Susan M. Kingsman, Stuart Naylor, Alan Melcher, Joanna Nicholls, Harpreet Wassan, Nagy Habib, Alan Anthoney, Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses Clinical Cancer Research. ,vol. 13, pp. 4487- 4494 ,(2007) , 10.1158/1078-0432.CCR-07-0704
Richard Harrop, Noel Drury, William Shingler, Priscilla Chikoti, Irina Redchenko, Miles W. Carroll, Susan M. Kingsman, Stuart Naylor, Richard Griffiths, Neil Steven, Robert E. Hawkins, Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunology, Immunotherapy. ,vol. 57, pp. 977- 986 ,(2008) , 10.1007/S00262-007-0428-7
Robert J. Amato, William Shingler, Madusha Goonewardena, Jackie de Belin, Stuart Naylor, Jaroslaw Jac, James Willis, Somyata Saxena, Joan Hernandez-McClain, Richard Harrop, Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α): A Phase 2 Trial Journal of Immunotherapy. ,vol. 32, pp. 765- 772 ,(2009) , 10.1097/CJI.0B013E3181ACE876
Richard A. Lake, Bruce W.S. Robinson, Immunotherapy and chemotherapy — a practical partnership Nature Reviews Cancer. ,vol. 5, pp. 397- 405 ,(2005) , 10.1038/NRC1613
Nancy E. Kemeny, Treatment of Metastatic Colon Cancer: "The Times They Are A-Changing" Journal of Clinical Oncology. ,vol. 31, pp. 1913- 1916 ,(2013) , 10.1200/JCO.2013.49.4500
Douglas Quan, Steven Gallinger, Cindy Nhan, Rebecca A. Auer, James J. Biagi, Glenn G. Fletcher, Calvin H.L. Law, Carol-Anne E. Moulton, Leyo Ruo, Alice C. Wei, Robin S. McLeod, The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review Surgery. ,vol. 151, pp. 860- 870 ,(2012) , 10.1016/J.SURG.2011.12.018
Robert J. Amato, Noel Drury, Stuart Naylor, Jaroslaw Jac, Somya Saxena, Amy Cao, Joan Hernandez-McClain, Richard Harrop, Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. Journal of Immunotherapy. ,vol. 31, pp. 577- 585 ,(2008) , 10.1097/CJI.0B013E31817DEAFD